Chi-Med's Innovative Drug Portfolio: Eight Candidates in 31 Trials

While announcing 2017 first-half financial results, Hutchison China MediTech (Chi-Med) provided a broad overview of its wide-ranging innovative drug portfolio. Comprised of eight drug small-molecule candidates, the portfolio is currently involved in 31 clinical trials. There are many signs of progress: earlier this year, Chi-Med filed its first NDA, a request for China approval of fruquintinib, a VEGFR inhibitor, as a treatment for colorectal cancer. Chi-Med also started its first global Phase III registration trial (for savolitinib), and it has five other pivotal Phase III studies underway with three more close to starting. More details.... Stock Symbol: (AIM/NSDQ: HCM) Share this with colleagues: // //